[
    [
        {
            "time": "2021-06-23",
            "original_text": "上海医药(02607.HK)注射用头孢曲松钠及注射用兰索拉唑通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "上海医药",
                    "注射用头孢曲松钠",
                    "注射用兰索拉唑",
                    "仿制药",
                    "一致性评价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)注射用头孢曲松钠及注射用兰索拉唑通过仿制药一致性评价",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-23",
            "original_text": "上海医药(601607.SH)：注射用头孢曲松钠及注射用兰索拉唑通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "上海医药",
                    "注射用头孢曲松钠",
                    "注射用兰索拉唑",
                    "仿制药",
                    "一致性评价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "上海医药(601607.SH)：注射用头孢曲松钠及注射用兰索拉唑通过仿制药一致性评价",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021",
            "original_text": "2021年全球医药产品市场规模及竞争格局分析 中国药企竞争力逐渐增强【组图】",
            "features": {
                "keywords": [
                    "全球医药市场",
                    "市场规模",
                    "竞争格局",
                    "中国药企",
                    "竞争力"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2021年全球医药产品市场规模及竞争格局分析 中国药企竞争力逐渐增强【组图】",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]